Back to top

crispr: Archive

Sundeep Ganoria

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.

VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change